Literature DB >> 2047886

Primary sclerosing cholangitis: a progressive disease?

M K Porayko1, N F LaRusso, R H Wiesner.   

Abstract

Patients with PSC should be viewed as having a disease that frequently progresses to liver failure if followed long enough. The rate of disease progression is variable and can occur without changes in symptoms or signs. With the advent of ERCP and widespread use of liver tests on routine examinations, the diagnosis of PSC is being made earlier and survival estimates have lengthened. Varying methods of survival analysis have also been responsible for differing opinions regarding the natural history of this disease. Nevertheless, it is probable that with close prospective, long-term follow-up, evidence of disease progression and increased mortality becomes apparent. Challenges for the future include being able to predict accurately the rate of disease progression and timing of liver failure in the individual patient. Preliminary studies using statistical survival modeling have been developed; however, further refinement of these models will be needed prior to application to clinical trials and liver transplantation.

Entities:  

Mesh:

Year:  1991        PMID: 2047886     DOI: 10.1055/s-2008-1040418

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  8 in total

Review 1.  Genetic epidemiology of primary sclerosing cholangitis.

Authors:  Tom-H Karlsen; Erik Schrumpf; Kirsten-Muri Boberg
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

Review 2.  Primary sclerosing cholangitis.

Authors:  Y Ueno; N F LaRusso
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

3.  Functional gadoxetate disodium-enhanced MRI in patients with primary sclerosing cholangitis (PSC).

Authors:  Heiko Hinrichs; Jan B Hinrichs; Marcel Gutberlet; Henrike Lenzen; Hans-Juergen Raatschen; Frank Wacker; Kristina I Ringe
Journal:  Eur Radiol       Date:  2015-07-24       Impact factor: 5.315

4.  Glucocorticoid receptors are downregulated in hepatic T lymphocytes in rats with experimental cholangitis.

Authors:  K Tjandra; T Le; M G Swain
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

5.  Complications and risk factors after ileal pouch-anal anastomosis for ulcerative colitis associated with primary sclerosing cholangitis.

Authors:  A H Kartheuser; R R Dozois; R H Wiesner; N F LaRusso; D M Ilstrup; C D Schleck
Journal:  Ann Surg       Date:  1993-04       Impact factor: 12.969

6.  Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis.

Authors:  Sunil Sheth; Julie C Shea; Michele D Bishop; Sanjiv Chopra; Meredith M Regan; Emily Malmberg; Carolyn Walker; Ryan Ricci; Lap-Chee Tsui; Peter R Durie; Julian Zielenski; Steven D Freedman
Journal:  Hum Genet       Date:  2003-06-03       Impact factor: 4.132

7.  Primary sclerosing cholangitis: sonographic findings.

Authors:  C B Majoie; N J Smits; S S Phoa; J W Reeders; P L Jansen
Journal:  Abdom Imaging       Date:  1995 Mar-Apr

8.  Experimental colitis attenuates development of toxin-induced cholangitis in rats.

Authors:  Kartika Tjandra; Tai Le; Mark G Swain
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.